These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

728 related items for PubMed ID: 30922297

  • 1. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
    Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D, Dienemann T, Schmieder RE.
    Cardiovasc Diabetol; 2019 Mar 29; 18(1):44. PubMed ID: 30922297
    [Abstract] [Full Text] [Related]

  • 2. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.
    Pietschner R, Kolwelter J, Bosch A, Striepe K, Jung S, Kannenkeril D, Ott C, Schiffer M, Achenbach S, Schmieder RE.
    Cardiovasc Diabetol; 2021 Nov 09; 20(1):219. PubMed ID: 34753480
    [Abstract] [Full Text] [Related]

  • 3. Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.
    Jung S, Bosch A, Kannenkeril D, Karg MV, Striepe K, Bramlage P, Ott C, Schmieder RE.
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov 01; 6(6):364-371. PubMed ID: 31816038
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
    Gessner A, Gemeinhardt A, Bosch A, Kannenkeril D, Staerk C, Mayr A, Fromm MF, Schmieder RE, Maas R.
    Cardiovasc Diabetol; 2022 Jan 06; 21(1):4. PubMed ID: 34991562
    [Abstract] [Full Text] [Related]

  • 6. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, Kawaguchi A, Ikehara Y, Machii N, Maruhashi T, Shima KR, Takamura T, Matsuzawa Y, Kimura K, Sakuma M, Oyama JI, Inoue T, Higashi Y, Ueda S, Node K, EMBLEM Trial Investigators.
    Cardiovasc Diabetol; 2017 Apr 12; 16(1):48. PubMed ID: 28403850
    [Abstract] [Full Text] [Related]

  • 7. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, Al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Jüni P, Zinman B, Connelly KA.
    Circulation; 2019 Nov 19; 140(21):1693-1702. PubMed ID: 31434508
    [Abstract] [Full Text] [Related]

  • 8. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
    Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE.
    Diabetes Obes Metab; 2015 Dec 19; 17(12):1180-93. PubMed ID: 26343814
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
    Tanaka A, Shimabukuro M, Teragawa H, Okada Y, Takamura T, Taguchi I, Toyoda S, Tomiyama H, Ueda S, Higashi Y, Node K, EMBLEM Investigators.
    Cardiovasc Diabetol; 2021 Jun 28; 20(1):105. PubMed ID: 34183012
    [Abstract] [Full Text] [Related]

  • 11. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
    Karg MV, Bosch A, Kannenkeril D, Striepe K, Ott C, Schneider MP, Boemke-Zelch F, Linz P, Nagel AM, Titze J, Uder M, Schmieder RE.
    Cardiovasc Diabetol; 2018 Jan 04; 17(1):5. PubMed ID: 29301520
    [Abstract] [Full Text] [Related]

  • 12. Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Zhao D, Liu H, Dong P.
    J Hum Hypertens; 2019 Apr 04; 33(4):327-339. PubMed ID: 30443007
    [Abstract] [Full Text] [Related]

  • 13. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V.
    J Am Heart Assoc; 2020 May 05; 9(9):e015716. PubMed ID: 32326806
    [Abstract] [Full Text] [Related]

  • 14. Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
    Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I, UTOPIA study investigators.
    Cardiovasc Diabetol; 2021 Jan 04; 20(1):4. PubMed ID: 33397376
    [Abstract] [Full Text] [Related]

  • 15. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
    Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, Broedl UC, Lund SS.
    Kidney Int; 2018 Jan 04; 93(1):231-244. PubMed ID: 28860019
    [Abstract] [Full Text] [Related]

  • 16. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M, Tahara N, Tahara A, Igata S, Honda A, Sugiyama Y, Nakamura T, Sun J, Kumashiro Y, Matsui T, Fukumoto Y, Yamagishi SI.
    Curr Vasc Pharmacol; 2019 Jan 04; 17(4):411-420. PubMed ID: 29766812
    [Abstract] [Full Text] [Related]

  • 17. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
    Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC.
    Cardiovasc Diabetol; 2014 Jan 29; 13():28. PubMed ID: 24475922
    [Abstract] [Full Text] [Related]

  • 18. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
    Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J.
    Cardiovasc Diabetol; 2017 Feb 27; 16(1):29. PubMed ID: 28241822
    [Abstract] [Full Text] [Related]

  • 19. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B, EMPA-REG OUTCOME Investigators.
    Circulation; 2018 Jan 09; 137(2):119-129. PubMed ID: 28904068
    [Abstract] [Full Text] [Related]

  • 20. Effect of 3-month therapy with empagliflozin on ambulatory blood pressure and arterial stiffness in patients with type 2 diabetes mellitus.
    Papazafiropoulou AK, Mpoumi L, Papantoniou S, Rallatou M, Antonopoulos S, Melidonis A.
    Ann Afr Med; 2021 Jan 09; 20(2):154-155. PubMed ID: 34213486
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.